www.fdanews.com/articles/120347-halozyme-doses-patient-for-clinical-trial-with-roche
Halozyme Doses Patient for Clinical Trial With Roche
September 10, 2009
Halozyme Therapeutics, Inc, a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, announced that the first patient was dosed in a Phase I pharmacokinetic clinical trial using Enhanze Technology (rHuPH20, recombinant human hyaluronidase) in a subcutaneous formulation of a Roche biologic.
MSN
MSN